KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash from Financing Activities (2016 - 2025)

Pacific Biosciences Of California has reported Cash from Financing Activities over the past 16 years, most recently at $1.5 million for Q3 2025.

  • Quarterly results put Cash from Financing Activities at $1.5 million for Q3 2025, up 80.91% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (up 107.97% YoY), and the annual figure for FY2025 was $3.4 million, up 107.97%.
  • Cash from Financing Activities for Q3 2025 was $1.5 million at Pacific Biosciences Of California, down from $2.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PACB hit a ceiling of $865.7 million in Q1 2021 and a floor of -$81.6 million in Q4 2023.
  • Median Cash from Financing Activities over the past 5 years was $1.3 million (2021), compared with a mean of $55.8 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 4656.97% in 2021 and later plummeted 10063.61% in 2023.
  • Pacific Biosciences Of California's Cash from Financing Activities stood at $1.3 million in 2021, then crashed by 38.14% to $819000.0 in 2022, then plummeted by 10063.61% to -$81.6 million in 2023, then soared by 38.48% to -$50.2 million in 2024, then soared by 102.93% to $1.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $1.5 million (Q3 2025), $2.0 million (Q1 2025), and -$50.2 million (Q4 2024) per Business Quant data.